Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy

Annals of Oncology

Volumn 27, Issue 10, 2016, Pages 1966-1969

  Novotny, J F ^a   Cogswell, J ^a   Inzunza, H ^a   Harbison, C ^a   Horak, C ^a   Averbuch, S ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EFFECTIVENESS; DRUG APPROVAL; DRUG SAFETY; GLIOBLASTOMA; HODGKIN DISEASE; HUMAN; MELANOMA; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RENAL CELL CARCINOMA; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TRANSITIONAL CELL CARCINOMA; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; NEOPLASM; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85019655033     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw288     Document Type: Editorial

References (19)

1. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639
2. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135
3. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550
4. Motzer RJ, Escudier B, McDermott DF et al.; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803-1813
5. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330
6. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-918
7. Chakravarti N, Prieto VG. Predictive factors of activity of anti-programmed death 1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl Lung Cancer Res 2015; 4: 743-751
8. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264
10. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467-477
11. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454
12. Dako PD-L1 IHC 28-8 pharmDX IFU. http://www.dako.com/download.pdf? objectid=128371002 (26 January 2016, date last accessed)
13. Phillips T, Simmons P, Inzunza HD et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol 2015; 23: 541-549
14. OPDIVO (Package Insert). Princeton, NJ: Bristol-Myers Squibb Company 2016
15. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34
16. Cagle PT, Bernicker CH. Challenges to biomarker testing for PD-1/PD-L1 checkpoint inhibitors for lung cancer. Arch Pathol Lab Med 2015; 139: 1477-1478
17. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14: 847-856
18. FDA. A blueprint proposal for companion diagnostic comparability. 2015 http://www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM439440.pdf. (27 January 2016, date last accessed)
19. Kerr KM, Tsao MS, Nicholson AG et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 2015; 10: 985-989